Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Biologics Contract Development Market Size Shifted, And What Is the Outlook Through 2034?
In the last few years, the size of the biologics contract development market has seen a swift increase. The industry is projected to expand from a worth of $7.75 billion in 2024 to $8.55 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.3%. Factors behind the growth during this historic period include an expansion of the biologics market, a surge in biopharmaceuticals, the complexity of biologics, patent expirations, and cost efficiency.
The market size of the biologics contract development is predicted to experience significant expansion in the coming years. Forecasted to attain a value of $13.08 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%, the growth can be credited to factors such as digitalization and data analytics, risk control measures, adaptability, scaling potential, increased investment in research and development, precision medical treatments, and individualized therapies. Key trends during this forecast period include advancements in regenerative medicine, strategic risk management, international partnerships, cutting-edge technologies, and technological unification.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Biologics Contract Development Market?
The escalating occurrence of long-term illnesses is anticipated to push the growth momentum of the biologics contract development market. Chronic diseases are illnesses with a duration of a year or more, requiring consistent medical care. With the increasing incidents of such diseases, the demand for innovative pharmaceuticals, including biologics, is on the rise. This, in turn, boosts the biologics contract development market. For instance, data from the Office for Health Improvement & Disparities, a UK government body, suggests that the first half of 2023 saw an excess of 3,940 deaths due to chronic lower respiratory diseases. This was a 30% surge when compared with anticipated rates. The number rose to 5,363 for the full year, indicating a 22% overall increase. Thus, the escalating prevalence of chronic diseases is anticipated to fuel the biologics contract development market’s growth.
Which Key Market Segments Comprise the Biologics Contract Development Market and Drive Its Revenue Growth?
The biologics contract developmentmarket covered in this report is segmented –
1) By Source: Microbial; Mammalian; Others Sources
2) By Indication: Oncology; Immunological Disorders; Cardiovascular Disorders; Hematological Disorders; Others Indications
3) By Product Service: Cell Line Development; Process Development; Others Product Services
Subsegments:
1) By Microbial: Bacterial Sources; Yeast Sources; Fungal Sources
2) By Mammalian: Chinese Hamster Ovary (CHO) Cells; Human Embryonic Kidney (HEK) Cells; Hybridoma Cells
3) By Other Sources: Plant-Based Systems; Insect Cell Systems; Algal Sources
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=8219&type=smp
Which Areas Are Leading Regions in the Biologics Contract Development Market Expansion Across the Globe?
North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theBiologics Contract Development Market Over the Coming Years?
The biologics contract development market is gaining momentum thanks to technological advancements. Prominent players in this sector are adopting novel technologies to maintain their market standing. For example, in January 2022, Lonza, a Swiss firm that provides contract manufacturing and development solutions, introduced the bYlok technology platform. This platform allows for the creation and manufacturing of bispecific antibodies, effectively resolving the light-heavy chain mismatch problem with high output, an accuracy rate exceeding 95%, and the capability to keep a mAb-like format. This technology is easily available to pharmaceutical and biotech companies via a straightforward research license.
View the full report here:
How Is the Biologics Contract Development Market Conceptually Defined?
Biologics contract development refers to companies that provide biologics development and manufacturing services to pharmaceutical corporations on a contract basis. The biologics contract development is used to outsource the manufacturing of biologics on contracts to focus on the marketing, R&D, and branding of products.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8219
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model